Longevity Health to merge with THPlasma in $59M all-stock deal; Biolabs terminated

Longevity Health Holdings, Inc.

Merger values THPlasma at $59M plus $20M earnout; Longevity shares at $3.00 (12% premium to July 11 close).
THPlasma has 5 plasma centers; FY2025E revenue $10M, EBITDA $2M; FY2026E revenue $32M, EBITDA $7M.
Post-closing (Q4 2025), Rajiv Shukla becomes Executive Chairman; George Chi becomes Co-Chairman & CEO.
Prior merger with 20/20 Biolabs automatically terminated July 8, 2025; no termination fees.
No cash condition precedent; approved by both boards, subject to stockholder and Nasdaq approvals.

item 1.01item 5.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.